Evaluating the Cost Effectiveness of Rapid Diagnostic Testing for the Identification of Pathogens and Resistance Genes in Bloodstream Infections

The model demonstrated improved patient survival and reduced average total costs with mRDT. The Cobas Eplex BCID panels, which have the largest pathogen coverage, reduced both mortality and overall costs compared with other mRDTs.